TY - JOUR
T1 - The Assessment of Convalescent Plasma Efficacy against COVID-19
AU - Casadevall, Arturo
AU - Grossman, Brenda J.
AU - Henderson, Jeffrey P.
AU - Joyner, Michael J.
AU - Shoham, Shmuel
AU - Pirofski, Liise anne
AU - Paneth, Nigel
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/12/18
Y1 - 2020/12/18
N2 - Antibody-based therapy for infectious diseases predates modern antibiotics and, in the absence of other therapeutic options, was deployed early in the SARS-CoV-2 pandemic through COVID-19 convalescent plasma (CCP) administration. Although most studies have demonstrated signals of efficacy for CCP, definitive assessment has proved difficult under pandemic conditions, with rapid changes in disease incidence and the knowledge base complicating the design and implementation of randomized controlled trials. Nevertheless, evidence from a variety of studies demonstrates that CCP is as safe as ordinary plasma and strongly suggests that it can reduce mortality if given early and with sufficient antibody content.
AB - Antibody-based therapy for infectious diseases predates modern antibiotics and, in the absence of other therapeutic options, was deployed early in the SARS-CoV-2 pandemic through COVID-19 convalescent plasma (CCP) administration. Although most studies have demonstrated signals of efficacy for CCP, definitive assessment has proved difficult under pandemic conditions, with rapid changes in disease incidence and the knowledge base complicating the design and implementation of randomized controlled trials. Nevertheless, evidence from a variety of studies demonstrates that CCP is as safe as ordinary plasma and strongly suggests that it can reduce mortality if given early and with sufficient antibody content.
UR - http://www.scopus.com/inward/record.url?scp=85101838108&partnerID=8YFLogxK
U2 - 10.1016/j.medj.2020.11.002
DO - 10.1016/j.medj.2020.11.002
M3 - Review article
C2 - 33363284
AN - SCOPUS:85101838108
SN - 2666-6359
VL - 1
SP - 66
EP - 77
JO - Med
JF - Med
IS - 1
ER -